FDA panel votes against painkiller from OxyContin maker


Save Story
Leer en español

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

WASHINGTON (AP) — Federal health advisers have overwhelmingly voted against a proposed painkiller from the maker of OxyContin due to risks of overdose.

Purdue Pharma is seeking FDA approval to market a harder-to-abuse version of the immediate-release drug oxycodone. The company already sells an extended-release formulation of the drug OxyContin, which is designed to thwart crushing or snorting.

But Food and Drug Administration panelists said an issue that delays the drug's absorption when taken with food poses a safety risk. The experts said it was unlikely patients would follow instructions to take the drug on an empty stomach. Instead patients could wind up taking multiple doses if they don't get the prompt pain relief they expect.

The panel voted 23-1 against approving the drug. The vote is a non-binding recommendation to the FDA.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Most recent Business stories

Related topics

Business
The Associated Press
    KSL.com Beyond Series

    KSL Weather Forecast

    KSL Weather Forecast
    Play button